Your browser doesn't support javascript.
loading
Euphorbia factor L1 suppresses breast cancer liver metastasis via DDR1-mediated immune infiltration.
Jiang, Dongjing; Gao, XiaoQin; Tan, RuLan; Liu, Xun; Zhu, Ye; Zhang, Li.
Afiliación
  • Jiang D; Traditional Chinese Medicine and Research Office, Suzhou Health College of Technology, Suzhou 215000, China.
  • Gao X; Jiangsu Key Laboratory for High Technology Research of TCM Formulae, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine and Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nan
  • Tan R; Traditional Chinese Medicine and Research Office, Suzhou Health College of Technology, Suzhou 215000, China.
  • Liu X; Traditional Chinese Medicine and Research Office, Suzhou Health College of Technology, Suzhou 215000, China.
  • Zhu Y; Traditional Chinese Medicine and Research Office, Suzhou Health College of Technology, Suzhou 215000, China.
  • Zhang L; Jiangsu Key Laboratory for High Technology Research of TCM Formulae, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine and Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nan
Aging (Albany NY) ; 15(17): 9217-9229, 2023 09 14.
Article en En | MEDLINE | ID: mdl-37709489
ABSTRACT
Euphorbia factor L1 (EFL1), a lathyrane-type diterpenoid from the medicinal herb Euphorbia lathyris L., has been documented to possess various pharmacologic actives. However, the function of EFL1 on breast cancer is not clear. In this study, we explored the effect and mechanism of EFL1 on breast cancer liver metastasis. Female BALB/c mice were subjected to breast cancer-surgical hepatic implantation (SHI) to establish breast cancer liver metastasis model in vivo. At 10 days post-surgery, mice were administrated with EFL1 once daily for a total of 2 weeks. Serum AST and ALT activities, abdominal circumference, peritoneal fluid, tumor weight and volume were determined to assess liver and mesenteric re-metastasis of breast cancer. H&E staining was used to observe morphology changes in tumor, liver and small intestine tissues. ELISA was applied to observe inflammatory levels. Tumor DDR1 expression and immune infiltration were determined using western blotting, immunohistochemistry and flow cytometer methods. Our results showed that EFL1 administration improved liver function (AST and ALT activities), ascites, liver metastasis and mesenteric re-metastasis in SHI mice. Also, SHI-induced inflammatory cell infiltration and IL-1ß, IL-6, TNF-α generation in ascites were decreased by EFL1 treatment. Mechanism study revealed that EFL1 intervention enhanced the ratios of CD4+ and CD8+ and CD49b+(NK) T lymphocytes and decreased Treg cells through downregulating DDR1 in the tumor of SHI mice. Furthermore, overexpression of DDR1 abolished the anti-liver metastasis effect and pro-immune infiltration action of EFL1 in SHI mice. Together, our findings suggested that EFL1 protects against breast cancer liver metastasis in vivo by targeting DDR1-mediated immune infiltration.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Primarias Secundarias / Diterpenos / Neoplasias Hepáticas / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Aging (Albany NY) Asunto de la revista: GERIATRIA Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Primarias Secundarias / Diterpenos / Neoplasias Hepáticas / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Aging (Albany NY) Asunto de la revista: GERIATRIA Año: 2023 Tipo del documento: Article País de afiliación: China